Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study will explore the effectiveness and safety of the combination therapy of anlotinib , penpulimab and SBRT in patients with metastatic non-small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
DRUG: Anlotinib Hydrochloride|DRUG: penpulimab|RADIATION: SBRT
Progression-free Survival, Time from enrollment to first observation of progression (RECIST1.1) or date of death (from any cause), Time Frame: up to approximately 2 year
Objective response rate, Proportion of patients with a complete or partial response as measured using RECIST 1.1 criteria, Time Frame: up to approximately 1 year|Overall Survival, Time from enrollment until death due to any cause, Time Frame: up to approximately 2 year|incidence, type and severity of adverse events, Descriptive statistics of safety will be presented using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, Time Frame: up to approximately 2 year
This study will explore the effectiveness and safety of the combination therapy of anlotinib , penpulimab and SBRT in patients with metastatic non-small Cell Lung Cancer (NSCLC)